Table 3.

Univariable and Multivariable Analysis of Overall Survival in the JHH cohort

Factors	Univariable analysis		Multivariable analysis
	HR (95% CI)	P	HR (95% CI)	P
Age
Age < 60	Ref
Age ≥ 60	1.03 (0.79–1.34)	0.86
Gender
Male	Ref
Female	1.14 (0.86–1.50)	0.36
Tumour site
Colon	Ref
Rectum	0.81 (0.58–1.14)	0.223
CRC Nodal metastases
Negative	Ref		Ref
Positive	1.48 (1.10–1.99)	0.01	1.55 (1.14–2.10)	<0.01
Disease-free interval
≥ 12months	Ref
< 12 months	1.18 (0.90–1.55)	0.243
Perioperative chemotherapy for CRLM
No	Ref
Yes	0.96 (0.63–1.44)	0.831
Preoperative CEA
<20	Ref		Ref
≥20	1.86 (1.41–2.47)	< 0.01	1.90 (1.43–2.53)	< 0.01
Extrahepatic disease
Negative	Ref		Ref
Positive	1.96 (1.28–3.00)	<0.01	2.10 (1.35–3.22)	<0.01
Bilobar disease
Negative	Ref
Positive	1.24 (0.95–1.62)	0.114
KRAS mutation status
Wild-type	Ref		Ref
Mutated	1.35 (1.02–1.78)	0.04	1.50 (1.13–2.00)	<0.01
Resection margin width
≥ 1mm	Ref		Ref
< 1mm	1.89 (1.39–2.56)	< 0.01	1.81 (1.32–2.48)	<0.01
Tumour burden score
< 3	Ref		Ref
≥ 3, < 9	1.70 (1.17–2.48)	<0.01	1.66 (1.14–2.44)	<0.01
≥ 9	3.00 (1.93–4.66)	< 0.01	3.23 (2.01–5.07)	< 0.01

CEA, carcinoembryonic antigen; CRC, colorectal cancer; CRLM, colorectal liver metastases; CI, confidence interval; HR, hazard ratio; Ref, reference